JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target

TL;DR


Summary:
- The article discusses key updates and announcements made by several major pharmaceutical companies at the 2023 J.P. Morgan Healthcare Conference.
- Biogen announced plans to focus on its core neuroscience portfolio, while Gilead and Merck shared updates on their respective pipeline developments.
- Cidara Therapeutics, Moderna, and Summit Therapeutics also provided updates on their ongoing research and clinical trials for various drug candidates.

Like summarized versions? Support us on Patreon!